keyword
https://read.qxmd.com/read/37670299/investigating-genomic-proteomic-and-post-transcriptional-regulation-profiles-in-colorectal-cancer-a-comparative-study-between-primary-tumors-and-associated-metastases
#21
JOURNAL ARTICLE
Hersh Ham-Karim, Ola Negm, Narmeen Ahmad, Mohammad Ilyas
INTRODUCTION: Approximately 50% of patients with primary colorectal carcinoma develop liver metastases. This study investigates the possible molecular discrepancies between primary colorectal cancer (pCRC) and their respective metastases. METHODS: A total of 22 pairs of pCRC and metastases were tested. Mutation profiling of 26 cancer-associated genes was undertaken in 22/22primary-metastasis tumour pairs using next-generation sequencing, whilst the expression of a panel of six microRNAs (miRNAs) was investigated using qPCRin 21/22 pairs and 22 protein biomarkers was tested using Reverse Phase Protein Array (RPPA)in 20/22 patients' tumour pairs...
September 5, 2023: Cancer Cell International
https://read.qxmd.com/read/37597576/increased-chemokine-ligand-26-expression-and-its-involvement-in-epithelial-mesenchymal-transition-in-the-endometrium-with-adenomyosis
#22
JOURNAL ARTICLE
Ai Ikebuchi, Mitsuhiko Osaki, Ikumi Wada, Hiroki Nagata, Kei Nagira, Yukihiro Azuma, Futoshi Okada, Tasuku Harada, Fuminori Taniguchi
OBJECTIVE: Adenomyosis is a gynecologic disorder characterized by symptoms of dysmenorrhea, abnormal uterine bleeding, and infertility. This study aimed to analyze the expression profiles of key inflammatory cytokines in the endometrium with adenomyosis and their involvement in epithelial-mesenchymal transition (EMT). STUDY DESIGN: Endometrial tissues collected from premenopausal women with (n = 3) or without (n = 3) adenomyosis during the secretory phase were subjected to DNA array analysis to examine inflammatory cytokines...
August 17, 2023: Journal of Gynecology Obstetrics and Human Reproduction
https://read.qxmd.com/read/37564024/erbb2-py-1248-as-a-predictive-biomarker-for-parkinson-s-disease-based-on-research-with-rppa-technology-and-in-vivo-verification
#23
JOURNAL ARTICLE
Meng Jin, Ruidie Shi, Daili Gao, Baokun Wang, Ning Li, Xia Li, Attila Sik, Kechun Liu, Xiujun Zhang
AIMS: This study aims to reveal a promising biomarker for Parkinson's disease (PD) based on research with reverse phase protein array (RPPA) technology for the first time and in vivo verification, which gains time for early intervention in PD, thus increasing the effectiveness of treatment and reducing disease morbidity. METHODS AND RESULTS: We employed RPPA technology which can assess both total and post-translationally modified proteins to identify biomarker candidates of PD in a cellular PD model...
August 11, 2023: CNS Neuroscience & Therapeutics
https://read.qxmd.com/read/37563685/lysin-k-specific-demethylase-1-inhibition-enhances-proteasome-inhibitor-response-and-overcomes-drug-resistance-in-multiple-myeloma
#24
JOURNAL ARTICLE
Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Maria Labrador, Monica Maccagno, Michela Cumerlato, Federico Oreglia, Lorenzo Prever, Veronica Manicardi, Elisa Taiana, Domenica Ronchetti, Mattia D'Agostino, Francesca Gay, Alessandra Larocca, Lenka Besse, Giorgio Roberto Merlo, Emilio Hirsch, Alessia Ciarrocchi, Giorgio Inghirami, Antonino Neri, Roberto Piva
BACKGROUND: Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and disease progression remain common. Therefore, a major challenge is the development of novel therapeutic approaches to overcome drug resistance, improve patient outcomes, and broaden PIs applicability to other pathologies...
August 10, 2023: Experimental Hematology & Oncology
https://read.qxmd.com/read/37532472/dynamic-nucleosome-remodeling-mediated-by-yy1-underlies-early-mouse-development
#25
JOURNAL ARTICLE
Mizuki Sakamoto, Shusaku Abe, Yuka Miki, Yusuke Miyanari, Hiroyuki Sasaki, Takashi Ishiuchi
Nucleosome positioning can alter the accessibility of DNA-binding proteins to their cognate DNA elements, and thus its precise control is essential for cell identity and function. Mammalian preimplantation embryos undergo temporal changes in gene expression and cell potency, suggesting the involvement of dynamic epigenetic control during this developmental phase. However, the dynamics of nucleosome organization during early development are poorly understood. In this study, using a low-input MNase-seq method, we show that nucleosome positioning is globally obscure in zygotes but becomes well defined during subsequent development...
July 1, 2023: Genes & Development
https://read.qxmd.com/read/37491309/pilot-clinical-trial-and-phenotypic-analysis-in-chemotherapy-pretreated-metastatic-triple-negative-breast-cancer-patients-treated-with-oral-tak-228-and-tak-117-piktor-to-increase-dna-damage-repair-deficiency-followed-by-cisplatin-and-nab-paclitaxel
#26
JOURNAL ARTICLE
Jessica D Lang, Tuong Vi V Nguyen, Maren K Levin, Page E Blas, Heather L Williams, Esther San Roman Rodriguez, Natalia Briones, Claudius Mueller, William Selleck, Sarah Moore, Victoria L Zismann, William P D Hendricks, Virginia Espina, Joyce O'Shaughnessy
BACKGROUND: A subset of triple-negative breast cancers (TNBCs) have homologous recombination deficiency with upregulation of compensatory DNA repair pathways. PIKTOR, a combination of TAK-228 (TORC1/2 inhibitor) and TAK-117 (PI3Kα inhibitor), is hypothesized to increase genomic instability and increase DNA damage repair (DDR) deficiency, leading to increased sensitivity to DNA-damaging chemotherapy and to immune checkpoint blockade inhibitors. METHODS: 10 metastatic TNBC patients received 4 mg TAK-228 and 200 mg TAK-117 (PIKTOR) orally each day for 3 days followed by 4 days off, weekly, until disease progression (PD), followed by intravenous cisplatin 75 mg/m2 plus nab paclitaxel 220 mg/m2 every 3 weeks for up to 6 cycles...
July 25, 2023: Biomarker Research
https://read.qxmd.com/read/37434432/identification-of-angiogenesis-related-genes-signature-for-predicting-survival-and-its-regulatory-network-in-glioblastoma
#27
JOURNAL ARTICLE
Zhiping Wan, Xiaokun Zuo, Siqiao Wang, Lei Zhou, Xiaojing Wen, Ying Yao, Jiefang Song, Juan Gu, Zhimin Wang, Ran Liu, Chun Luo
Glioblastoma (GBM) is notorious for malignant neovascularization that contributes to undesirable outcome. However, its mechanisms remain unclear. This study aimed to identify prognostic angiogenesis-related genes and the potential regulatory mechanisms in GBM. RNA-sequencing data of 173 GBM patients were obtained from the Cancer Genome Atlas (TCGA) database for screening differentially expressed genes (DEGs), differentially transcription factors (DETFs), and reverse phase protein array (RPPA) chips. Differentially expressed genes from angiogenesis-related gene set were extracted for univariate Cox regression analysis to identify prognostic differentially expressed angiogenesis-related genes (PDEARGs)...
July 11, 2023: Cancer Medicine
https://read.qxmd.com/read/37337282/scutellaria-baicalensis-enhances-5-fluorouracil-based-chemotherapy-via-inhibition-of-proliferative-signaling-pathways
#28
JOURNAL ARTICLE
Haizhou Liu, Hui Liu, Zhiyi Zhou, Jessica Chung, Guojing Zhang, Jin Chang, Robert A Parise, Edward Chu, John C Schmitz
Fluoropyridine-based chemotherapy remains the most widely used treatment for colorectal cancer (CRC). In this study, we investigated the mechanism by which the natural product Scutellaria baicalensis (Huang Qin; HQ) and one of its main components baicalin enhanced 5-fluorouracil (5-FU) antitumor activity against CRC. Cell proliferation assays, cell cycle analysis, reverse-phase protein array (RPPA) analysis, immunoblot analysis, and qRT-PCR were performed to investigate the mechanism(s) of action of HQ and its active components on growth of CRC cells...
June 19, 2023: Cell Communication and Signaling: CCS
https://read.qxmd.com/read/37296634/the-vicious-cycle-of-melanoma-microglia-crosstalk-inter-melanoma-variations-in-the-brain-metastasis-promoting-il-6-jak-stat3-signaling-pathway
#29
JOURNAL ARTICLE
Sivan Izraely, Shlomit Ben-Menachem, Sapir Malka, Orit Sagi-Assif, Matias A Bustos, Orit Adir, Tsipi Meshel, Maharrish Chelladurai, Suyeon Ryu, Romela I Ramos, Metsada Pasmanik-Chor, Dave S B Hoon, Isaac P Witz
Previous studies from our lab demonstrated that the crosstalk between brain-metastasizing melanoma cells and microglia, the macrophage-like cells of the central nervous system, fuels progression to metastasis. In the present study, an in-depth investigation of melanoma-microglia interactions elucidated a pro-metastatic molecular mechanism that drives a vicious melanoma-brain-metastasis cycle. We employed RNA-Sequencing, HTG miRNA whole transcriptome assay, and reverse phase protein arrays (RPPA) to analyze the impact of melanoma-microglia interactions on sustainability and progression of four different human brain-metastasizing melanoma cell lines...
May 30, 2023: Cells
https://read.qxmd.com/read/37287368/valosin-containing-protein-vcp-p97-is-prognostically-unfavorable-in-pediatric-aml-and-negatively-correlates-with-unfolded-protein-response-proteins-ire1-and-grp78-a-report-from-the-children-s-oncology-group
#30
JOURNAL ARTICLE
Fieke W Hoff, Yihua Qiu, Brandon D Brown, Robert B Gerbing, Amanda R Leonti, Rhonda E Ries, Alan S Gamis, Richard Aplenc, Edward Anders Kolb, Todd A Alonzo, Soheil Meshinchi, Gaye N Jenkins, Terzah M Horton, Steven M Kornblau
PURPOSE: The endoplasmic reticulum (ER) is the major site of protein synthesis and folding in the cell. ER-associated degradation (ERAD) and unfolded protein response (UPR) are the main mechanisms of ER-mediated cell stress adaptation. Targeting the cell stress response is a promising therapeutic approach in acute myeloid leukemia (AML). EXPERIMENTAL DESIGN: Protein expression levels of valosin-containing protein (VCP), a chief element of ERAD, were measured in peripheral blood samples from in 483 pediatric AML patients using reverse phase protein array methodology...
June 7, 2023: Proteomics. Clinical Applications
https://read.qxmd.com/read/37280713/targeting-cxcr4-abrogates-resistance-to-trastuzumab-by-blocking-cell-cycle-progression-and-synergizes-with-docetaxel-in-breast-cancer-treatment
#31
JOURNAL ARTICLE
Shuying Liu, Shelly M Xie, Wenbin Liu, Mihai Gagea, Ariella B Hanker, Nguyen Nguyen, Akshara Singareeka Raghavendra, Gloria Yang-Kolodji, Fuliang Chu, Sattva S Neelapu, Adriano Marchese, Samir Hanash, Johann Zimmermann, Carlos L Arteaga, Debasish Tripathy
BACKGROUND: Although trastuzumab and other HER2-targeted therapies have significantly improved survival in patients with HER2 overexpressed or amplified (HER2+) breast cancer, a significant proportion of patients do not respond or eventually develop clinical resistance. Strategies to reverse trastuzumab resistance remain a high clinical priority. We were the first to report the role of CXCR4 in trastuzumab resistance. The present study aims to explore the therapeutic potential of targeting CXCR4 and better understand the associated mechanisms...
June 6, 2023: Breast Cancer Research: BCR
https://read.qxmd.com/read/37280243/establishment-and-characterization-of-patient-derived-xenograft-of-a-rare-pediatric-anaplastic-pleomorphic-xanthoastrocytoma-pxa-bearing-a-cdc42se2-braf-fusion
#32
JOURNAL ARTICLE
Nur P Damayanti, M Reza Saadatzadeh, Erika Dobrota, Josue D Ordaz, Barbara J Bailey, Pankita H Pandya, Khadijeh Bijangi-Vishehsaraei, Harlan E Shannon, Anthony Alfonso, Kathy Coy, Melissa Trowbridge, Anthony L Sinn, Zhong-Yin Zhang, Rosa I Gallagher, Julia Wulfkuhle, Emanuel Petricoin, Angela M Richardson, Mark S Marshall, Alex Lion, Michael J Ferguson, Karl E Balsara, Karen E Pollok
Pleomorphic xanthoastrocytoma (PXA) is a rare subset of primary pediatric glioma with 70% 5-year disease free survival. However, up to 20% of cases present with local recurrence and malignant transformation into more aggressive type anaplastic PXA (AXPA) or glioblastoma. The understanding of disease etiology and mechanisms driving PXA and APXA are limited, and there is no standard of care. Therefore, development of relevant preclinical models to investigate molecular underpinnings of disease and to guide novel therapeutic approaches are of interest...
June 6, 2023: Scientific Reports
https://read.qxmd.com/read/37279095/adavosertib-enhances-antitumor-activity-of-trastuzumab-deruxtecan-in-her2-expressing-cancers
#33
JOURNAL ARTICLE
Timothy P DiPeri, Kurt W Evans, Maria Gabriela Raso, Ming Zhao, Yasmeen Q Rizvi, Xiaofeng Zheng, Bailiang Wang, Bryce P Kirby, Kathleen Kong, Michael Kahle, Timothy A Yap, Ecaterina E Ileana Dumbrava, Jaffer A Ajani, Siqing Fu, Khandan Keyomarsi, Funda Meric-Bernstam
PURPOSE: Cyclin E (CCNE1) has been proposed as a biomarker of sensitivity to adavosertib, a Wee1 kinase inhibitor, and a mechanism of resistance to HER2-targeted therapy. EXPERIMENTAL DESIGN: Copy number and genomic sequencing data from The Cancer Genome Atlas and MD Anderson Cancer Center databases were analyzed to assess ERBB2 and CCNE1 expression. Molecular characteristics of tumors and patient-derived xenografts were assessed by next-generation sequencing, whole-exome sequencing, fluorescent in situ hybridization, and immunohistochemistry...
June 6, 2023: Clinical Cancer Research
https://read.qxmd.com/read/37261265/anesthetics-inhibit-phosphorylation-of-the-ribosomal-protein-s6-in-mouse-cultured-cortical-cells-and-developing-brain
#34
JOURNAL ARTICLE
Matthew B Friese, Taranjit S Gujral, Arvind Palanisamy, Brittany Hemmer, Deborah J Culley, Gregory Crosby
INTRODUCTION: The development and maintenance of neural circuits is highly sensitive to neural activity. General anesthetics have profound effects on neural activity and, as such, there is concern that these agents may alter cellular integrity and interfere with brain wiring, such as when exposure occurs during the vulnerable period of brain development. Under those conditions, exposure to anesthetics in clinical use today causes changes in synaptic strength and number, widespread apoptosis, and long-lasting cognitive impairment in a variety of animal models...
2023: Frontiers in Aging Neuroscience
https://read.qxmd.com/read/37237151/comparative-analysis-of-deeply-phenotyped-gbm-cohorts-of-short-term-and-long-term-survivors
#35
JOURNAL ARTICLE
Archita Biswas, Manuela Salvucci, Kate Connor, Heiko Düssmann, Steven Carberry, Michael Fichtner, Ellen King, Brona Murphy, Alice C O'Farrell, Jane Cryan, Alan Beausang, Josephine Heffernan, Mattia Cremona, Bryan T Hennessy, James Clerkin, Kieron J Sweeney, Steve MacNally, Francesca Brett, Philip O'Halloran, Orna Bacon, Simon Furney, Maite Verreault, Emie Quissac, Franck Bielle, Mohammed H Ahmed, Ahmed Idbaih, Sieger Leenstra, Ioannis Ntafoulis, Federica Fabro, Martine Lamfers, Anna Golebiewska, Frank Hertel, Simone P Niclou, Romain Tching Chi Yen, Andreas Kremer, Gonca Dilcan, Francesca Lodi, Ingrid Arijs, Diether Lambrechts, Manasa Kalya Purushothama, Alexander Kel, Annette T Byrne, Jochen H M Prehn
BACKGROUND: Glioblastoma (GBM) is an aggressive brain cancer that typically results in death in the first 15 months after diagnosis. There have been limited advances in finding new treatments for GBM. In this study, we investigated molecular differences between patients with extremely short (≤ 9 months, Short term survivors, STS) and long survival (≥ 36 months, Long term survivors, LTS). METHODS: Patients were selected from an in-house cohort (GLIOTRAIN-cohort), using defined inclusion criteria (Karnofsky score > 70; age < 70 years old; Stupp protocol as first line treatment, IDH wild type), and a multi-omic analysis of LTS and STS GBM samples was performed...
May 26, 2023: Journal of Neuro-oncology
https://read.qxmd.com/read/37219859/fibronectin-contributes-to-a-braf-inhibitor-driven-invasive-phenotype-in-thyroid-cancer-through-egr1-which-can-be-blocked-by-inhibition-of-erk1-2
#36
JOURNAL ARTICLE
Hannah M Hicks, Nikita Pozdeyev, Sharon B Sams, Umarani Pugazhenthi, Elise S Bales, Marie-Claude Hofmann, Logan R McKenna, Rebecca E Schweppe
Mutations in BRAF are common in advanced papillary and anaplastic thyroid cancer (PTC and ATC). However, BRAF-mutant PTC patients currently lack therapies targeting this pathway. Despite the approved combination of BRAF and MEK1/2 inhibition for patients with BRAF-mutant ATC, these patients often progress. Thus, we screened a panel of BRAF-mutant thyroid cancer cell lines to identify new therapeutic strategies. We showed that thyroid cancer cells resistant to BRAF inhibition (BRAFi) exhibit an increase in invasion and a pro-invasive secretome in response to BRAFi...
May 23, 2023: Molecular Cancer Research: MCR
https://read.qxmd.com/read/37173995/regulation-of-vegfr2-and-akt-signaling-by-musashi-2-in-lung-cancer
#37
JOURNAL ARTICLE
Igor Bychkov, Iuliia Topchu, Petr Makhov, Alexander Kudinov, Jyoti D Patel, Yanis Boumber
Lung cancer is the most frequently diagnosed cancer type and the leading cause of cancer-related deaths worldwide. Non-small cell lung cancer (NSCLC) represents most of the diagnoses of lung cancer. Vascular endothelial growth factor receptor-2 (VEGFR2) is a member of the VEGF family of receptor tyrosine kinase proteins, which are expressed on both endothelial and tumor cells, are one of the key proteins contributing to cancer development, and are involved in drug resistance. We previously showed that Musashi-2 (MSI2) RNA-binding protein is associated with NSCLC progression by regulating several signaling pathways relevant to NSCLC...
April 28, 2023: Cancers
https://read.qxmd.com/read/37169592/antibody-reliability-influences-observed-mrna-protein-correlations-in-tumour-samples
#38
JOURNAL ARTICLE
Swathi Ramachandra Upadhya, Colm J Ryan
Reverse phase protein arrays (RPPA) have been used to quantify the abundance of hundreds of proteins across thousands of tumour samples in the Cancer Genome Atlas. By number of samples, this is the largest tumour proteomic dataset available and it provides an opportunity to systematically assess the correlation between mRNA and protein abundances. However, the RPPA approach is highly dependent on antibody reliability and approximately one-quarter of the antibodies used in the the Cancer Genome Atlas are deemed to be somewhat less reliable...
August 2023: Life Science Alliance
https://read.qxmd.com/read/37093162/optically-controlled-construction-of-three-dimensional-protein-arrays
#39
JOURNAL ARTICLE
Qing Liu, Yu Zhou, Ahmed Shaukat, Zhuojun Meng, Daniella Kyllönen, Iris Seitz, Daniel Langerreiter, Kim Kuntze, Arri Priimagi, Lifei Zheng, Mauri Aleksi Kostiainen
Protein crystallization is an important tool for structural biology and nanostructure preparation. Here, we report on kinetic pathway-dependent protein crystals that are controlled by light. Photo-responsive crystallites are obtained by complexing the model proteins with cationic azobenzene dyes. The crystalline state is readily switched to a dispersed phase under ultra-violet light and restored by subsequent visible light illumination. The switching can be reversibly repeated for multiple cycles without noticeable structure deterioration...
April 24, 2023: Angewandte Chemie
https://read.qxmd.com/read/37088806/combined-inhibition-of-bcl-2-and-mcl-1-overcomes-bax-deficiency-mediated-resistance-of-tp53-mutant-acute-myeloid-leukemia-to-individual-bh3-mimetics
#40
JOURNAL ARTICLE
Bing Z Carter, Po Yee Mak, Wenjing Tao, Edward Ayoub, Lauren B Ostermann, Xuelin Huang, Sanam Loghavi, Steffen Boettcher, Yuki Nishida, Vivian Ruvolo, Paul E Hughes, Phuong K Morrow, Torsten Haferlach, Steven Kornblau, Muharrem Muftuoglu, Michael Andreeff
TP53-mutant acute myeloid leukemia (AML) respond poorly to currently available treatments, including venetoclax-based drug combinations and pose a major therapeutic challenge. Analyses of RNA sequencing and reverse phase protein array datasets revealed significantly lower BAX RNA and protein levels in TP53-mutant compared to TP53-wild-type (WT) AML, a finding confirmed in isogenic CRISPR-generated TP53-knockout and -mutant AML. The response to either BCL-2 (venetoclax) or MCL-1 (AMG176) inhibition was BAX-dependent and much reduced in TP53-mutant compared to TP53-WT cells, while the combination of two BH3 mimetics effectively activated BAX, circumventing survival mechanisms in cells treated with either BH3 mimetic, and synergistically induced cell death in TP53-mutant AML and stem/progenitor cells...
April 24, 2023: Blood Cancer Journal
keyword
keyword
79091
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.